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Abstract. Standard Raman spectroscopy (SRS) is a noninvasive technique that is used in the biomedical field
to discriminate between normal and cancer cells. However, the presence of a strong fluorescence background
detracts from the use of SRS in real-time clinical applications. Recently, we have reported a novel modulated
Raman spectroscopy (MRS) technique to extract the Raman spectra from the background. In this paper, we present
the first application of MRS to the identification of human urothelial cells (SV-HUC-1) and bladder cancer cells
(MGH) in urine samples. These results are compared to those obtained by SRS. Classification using the principal
component analysis clearly shows that MRS allows discrimination between Raman spectra of SV-HUC-1 andMGH
cells with high sensitivity (98%) and specificity (95%). MRS is also used to distinguish between SV-HUC-1 and
MGH cells after exposure to urine for up to 6 h. We observe a marked change in the MRS of SV-HUC-1 and MGH
cells with time in urine, indicating that the conditions of sample collection will be important for the application of
this methodology to clinical urine samples. C©2011 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.3556722]
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1 Introduction
Currently, a variety of diagnostic tests are used to detect bladder
cancer.1 However, these techniques are costly and time consum-
ing for both hospitals and patients. In addition, most of these
diagnostic tools require the expertise of a cytopathologist, radi-
ologist (e.g., intravenous urography, computed tomography and
magnetic resonance urography), or urologist (e.g., cystoscopy).
This approach is the underlying reason for a “lack of progress”
in the early diagnosis of bladder cancer.1 A delay in the detection
of invasive bladder cancer increases the risk of bladder cancer
death.2 Therefore, it is crucial to develop an inexpensive, nonin-
vasive, highly sensitive, rapid, and easily automated technique
to diagnose bladder cancer in its early stages.
In the last decade, Raman spectroscopy (RS) has been used
for the discrimination of normal cells from bladder and prostate
cancer cells on the basis of their biochemical fingerprints.3 RS
has considerable potential as a diagnostic tool for the classifi-
cation of normal and cancer cells due to its noninvasive nature
and capability to predict pathological diagnosis in real time.4
However, the use of this spectroscopic technique is dramatically
limited by the presence of strong fluorescence signals. These oc-
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cur in the same spectral window as the inherently weak Raman
signals from biomedical samples and therefore hide these Raman
peaks. In the last 30 years several fluorescence-suppression
methods have been developed, all with the aim of removing the
fluorescence background and isolating the Raman signals.5–11
These methods include polynomial fitting,10 time-resolved
Raman spectroscopy,12 polarization modulation technique,13
and shifted excitation Raman difference spectroscopy.14 Though
each of these techniques has been demonstrated to be useful in
specific situations, they are not without limitations.
Recently, we developed a simple innovative method, mod-
ulated Raman spectroscopy (MRS), that is able to filter out
the Raman spectra from the fluorescence background.15, 16 The
method is based on the wavelength shift of the Raman peaks as
the wavelength of the excitation laser is continuously modulated
while the fluorescence background remains static. By using an
algorithm based on principal component analysis (PCA) of the
raw data, mostly fluorescence-free Raman spectra are obtained.
This method exposes even very weak Raman features generally
masked by the fluorescence. Additionally, the signal-to-noise ra-
tio of the modulated Raman spectra is greatly improved, reduc-
ing the necessary accumulation time and permitting real-time
applications.
In this paper, we present the application of MRS to the iden-
tification of fixed urothelial and bladder tumor cells exposed to
urine for up to 6 h. We model the effects of urine on exfoliated
cells by using urothelial and malignant human bladder cell lines.
We validate the use of the MRS technique to discriminate be-
tween fixed urothelial cells and cancer cells not exposed to urine
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Fig. 1 Experimental setup (not to scale): A laser beam is expanded through a telescope formed by Lens #1 and Lens # 2 lenses and reflected from
a 45◦ holographic notch filter (HNF) and focused on the sample by an objective lens (50×). The Raman scatter from the sample is collected by the
same microscope objective and filtered by the same HNF. It is then guided toward the spectrometer and acquired via a liquid nitrogen cooled CCD
camera.
by comparing modulated Raman (MR) spectra of these cells to
the corresponding standard Raman (SR) spectra. The ability of
MRS compared to standard Raman spectroscopy (SRS) to clas-
sify urothelial cells and cancer cells is then assessed by carrying
out PCA on both the SR and MR spectra. We then mimic a sce-
nario closer to a real clinical setting by exposing urothelial cells
and bladder cancer cells to urine for different lengths of time up
to 6 h. The ability of MRS to classify urothelial cells and cancer
cells correctly in urine is assessed by multivariate analysis.
2 Materials and Methods
2.1 Experimental Set-Up
The MR microscopy system is shown in Fig. 1. The setup is iden-
tical to that used for standard Raman17 but for the laser which is a
tunable diode laser (Sacher Lasertechnik, TEC-520–0780-100,
external cavity diode laser in a Littman configuration, total tun-
ing range 25 nm) operating at 785 nm and with a maximum
power of 100 mW. Additionally, an external arbitrary wave-
form/function generator (Keithley, 3390 50 MHz) is connected
to the tunable laser to modulate the wavelength at frequencies
as low as a few millihertz.
2.2 Cell Lines and Sample Preparation
Human urothelial cells (SV-HUC-1) were cultured in the fol-
lowing medium: F-12 nutrient mixture with L-glutamine (Ham-
GIBCO 21765), with added human insulin 5 μg/ml, hydro-
cortisone 1 μg/ml, transferrin 5 μg/ml, glucose 2.7 mg/ml
(Sigma), nonessential amino acids 0.1 mM (Gibco), penicillin
100μg/ml, streptomycin 100 U/ml (Sigma), and fetal calf serum
1% (Globepharm). The SV-HUC-1 cells had been immortalized
by transformation with simian virus 40 (SV40).18
A cell line derived from a recurrent human bladder tumor
(MGH-U1) was maintained in long-term culture.19 It has been
shown that the MGH cell line is the same as the T24 cell line, also
derived from a recurrent bladder tumor.20 MGH-U1 cells were
cultured in the following medium: GIBCO D-MEM:F12 (1:1)
with added fetal calf serum 7% (Globepharm), penicillin 100
μg/ml, L-glutamine 2 mM, and streptomycin 100 U/ml (Sigma).
Cells from each cell line were incubated for up to 6 h in a
fresh urine sample that had been filtered through a 0.22-μm Mil-
lipore filter. These samples were collected from healthy donors
with full ethical approval (approval number MD5091). Cell
viability was assessed by sampling the cells at different times
in urine and incubating the cells with 1% Fast Green [CI (color
index number) 42053, Sigma Chemical Co. Ltd.] for 5 min. The
proportion of cells that excluded the dye was recorded.
Further samples incubated in urine were diluted in a large
volume of medium and plated in microtiter plates to assess their
reproductive capacity. Following 4 days culture, viability was
assessed by adding 10 μl of cell counting reagent (Dojindo kit
CK04) and incubating the plates for a further 3 h, after which
the optical density was measured using a Dynex MRX reader at
a wavelength of 450 nm.
To prepare the samples, cells from each cell line were
incubated in urine for different lengths of time up to 6 h. At 0 h
(control), 30 min, 3 and 6 h, PreservCyt (Cytec, UK) was added
at a ratio of 2 parts urine to 1 part PreservCyt. The cells were
then pelleted by centrifugation at 600 g for 10 min and resus-
pended in PreservCyt for storage at 4◦C. Samples for Raman
analysis were washed extensively in phosphate-buffered saline
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Fig. 2 (a) Mean standard Raman spectrum of fixed urothelial (SV-HUC-1) and bladder cancer cells (MGH) not exposed to urine (control). (b) Zoom
on region 1100 to 1300 cm−1. (c) Mean modulated Raman spectra of control fixed SV-HUC-1 and bladder cancer MGH cells. (d) Zoom on region
1100 to 1300 cm−1.
(PBS) and re-suspended in 100 μl of PBS to concentrate the
cells.
The sample chamber used in the Raman experiments was
made by using a 80-μm deep vinyl spacer between a quartz
slide (1 mm in thickness) and a quartz coverslip (150 μm in
thickness) (UQG, United Kingdom). 20 μl of cell suspension
was placed inside the chamber and the cells were allowed to
sediment onto the inverted quartz coverslip for ∼30 min before
starting the Raman experiments.
2.3 Method and Spectral Analysis
Single cell standard spectra were acquired from 40 fixed urothe-
lial cells (SV-HUC-1) and 40 fixed bladder cancer cells (MGH
cells) exposed to urine for 0 h (control), 30 min, 3 and 6 h. The
background spectra were also acquired. The laser power on the
sample during signal acquisition was ∼8 mW, and each spec-
trum was collected in the range from 500 to 2100 cm− 1 with
an integration time of 200 s. The laser beam, during acquisition,
was focused on the cell nucleus.
For each cell, 40 stacked spectra were recorded with an acqui-
sition time of 5 s each while the laser wavelength was modulated
with a ramp wave of 50% symmetry, a modulation frequency of
40 mHz, and a modulation amplitude of 60 GHz (corresponding
to 0.2 nm at this wavelength). The 40 stacked spectra were then
analyzed by using a custom designed MATLAB script based on
the PCA method for fluorescence suppression, and modulated
Raman spectra of the cells were obtained. These modulation pa-
rameters were chosen to maximize the signal-to-noise ratio (data
not shown). Indeed, higher modulation frequencies decrease the
1/f noise level while increasing the shot noise.16
To evaluate the SR and MR spectra of control and urine-
stressed HUC and MGH cells and to compare different
cell classes against each other, PCA21 was carried out. The
specificity/sensitivity and, more generally, the confusion matrix
was determined using a leave-one-out procedure in which each
spectrum is classified against the PCA of all the other spectra.
The overall efficiency was defined as the proportion of cells
classified correctly.
3 Results and Discussion
3.1 Cell Viability
The viability of both the urothelial cells and the bladder tumor
cells decreased with time in urine as assessed by dye exclusion.
After 1 h the viability decreased to (60 ± 2)% for the tumor
cells and (64 ± 4)% for the urothelial cell line. In contrast,
the reproductive capacity of both cells decreased rapidly after
incubation in urine. After 20 min the tumor cells had almost
completely lost reproductive integrity and the urothelial cells
demonstrated a similar decline by 40 min.
3.2 Standard and Modulated Raman Spectra for
Control Fixed SV-HUC-1 and MGH Cells
To test the robustness of the MRS technique compared to SRS,
fixed urothelial cells (SV-HUC-1) and bladder cancer cells
(MGH) not exposed to urine (control) were characterized by
both MRS and SRS.
Figure 2 displays the mean Raman spectra obtained by SRS
and MRS. SR spectra of SV-HUC-1 and MGH cells [Fig. 2(a)]
show a strong fluorescence background generated from the
quartz surfaces of the sample chamber and some cell autoflu-
orescence. It is clear that SRS does not allow the finest details
of the Raman features of the cells to be defined, thus making it
difficult to assign precisely the various chemical constituents in
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Fig. 3 (a) First four principal components generated by the analysis of SR spectra for control MGH cells. (b) First two principal components generated
by the analysis of MR spectra for control MGH cells.
the analyzed sample [Fig. 2(b)]. Conversely, in the MR spectra
of SV-HUC-1 and MGH cells [Fig. 2(c)] the Raman peaks of
the chemical constituents of the cells can be clearly observed
[Figs.2(c) and 2(d)]. This facilitates the assignment of individ-
ual peaks based on previous data.22 To carry out an objective
comparison between the urothelial cell (SV-HUC-1) and cancer
cell (MGH) spectra, each spectrum is normalized to the height
of the double peak in the region 950 to 1100 cm− 1. This nor-
malization is applied to the whole spectrum. Comparing the rel-
ative intensities of the spectral peaks for SV-HUC-1 and MGH
spectra show that urothelial cells (SV-HUC-1) are characterized
by relatively strong protein and carbohydrate Raman peaks, in
the spectral region 1100 to 1300 cm− 1, which suggest greater
concentrations of proteins and carbohydrates in nonmalignant
cells.23 In contrast, the spectra from bladder cancer cells (MGH)
show a significant increase in the peaks pertaining to ring breath-
ing modes in DNA bases, such as 669, 727, 785, 828, 1095, and
1578 cm− 1, suggesting an increase in the DNA concentration of
bladder cancer cells. Tumor cells commonly exhibit an increase
in DNA content in the nucleus.
The ability of modulated Raman spectroscopy, compared to
standard Raman spectroscopy, to discriminate between control
urothelial cells (SV-HUC-1) and bladder cancer cells (MGH)
was assessed using PCA. In the PCA carried out on the SR and
MR spectra of the SV-HUC-1 and MGH cells, 40 SV-HUC-1
spectra were compared with 40 MGH spectra.
As clearly observed in Fig. 2(a), the standard spectra show a
very strong background intensity (cell autofluorescence), upon
which the Raman spectra are superimposed. This behavior is
also clearly visible in the first two principal components shown
in Fig. 3(a).
PC1 and PC2 of the SR spectra appear predominantly to
describe the inter-sample variation in autofluorescence, which
cannot be directly attributed to the cellular changes that distin-
guish the samples. To support this argument we used the Fourier
transform (FT) to estimate the difference between the slow vary-
ing background and the sharp Raman bands. Indeed, the FT of a
slowly varying signal contains only low frequency components
while sharp/fast variations imply high frequency components.
Here, we calculate the FT along the wavenumber axis of the
first four principal component spectra. In the Fourier space the
broad background signal is visible at low frequencies, while the
sharp Raman peaks are present at high frequencies. Using this
approach, we observe that the most important Raman variations
between SV-HUC-1 and MGH standard spectra are given by the
3rd and 4th PCs and, therefore, the 1st and 2nd PCs are not taken
into account. Thus, the discrimination between SV-HUC-1 and
MGH standard spectra was based on the 3rd and 4th PCs as
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Fig. 4 (a) PCA of all individual SR spectra and (b) PCA of all individual
MR spectra for 40 control SV-HUC-1 and 40 MGH cells.
shown in Fig. 4(a). The two cell types do not form distinct and
separate clusters, giving a sensitivity of 97% and a specificity
of 72%.
The spectra recorded via MR spectroscopy have advantages
over the SR spectra when used in a multivariate analysis such
as PCA. First, PCA relies on a normal distribution of the
noise, which might not be the case for SR spectroscopy due
to the positive nature of the spectral intensity. On the contrary,
the MR spectra oscillate between negative and positive values
[Fig. 2(b)] and therefore the noise of the MR spectra can have
a normal distribution. Further, MR spectra are background-free
and the Raman contribution is already present in the first two
PCs as clearly observed in Fig. 3(b).
The plot of the first two main PCs for the MR spectra of
SV-HUC-1 and MGH cells are shown in Fig. 4(b), revealing the
presence of two very distinct clusters, one for SV-HUC-1 cells
and the other for MGH cells. These findings indicate that when
Fig. 5 PCA of all individual MR spectra for 40 SV-HUC-1 and 40MGH
cells exposed to urine for 6 h.
PCA is carried out on the MR spectra its ability to discriminate
between SV-HUC-1 and MGH cells is improved. Therefore, the
1st and 2nd components, containing the most pertinent Raman
information, can be used to discriminate between SV-HUC-1
and MGH modulated spectra resulting in excellent sensitivity
(98%) and specificity (95%).
3.3 Modulated Raman Spectroscopy of
Urine-Stressed Urothelial Cells (SV-HUC-1) and
Bladder Cancer Cells (MGH)
To mimic a scenario as close as possible to a clinical setting, the
effects of urine on the Raman spectra and hence the biochemistry
of urothelial cells (SV-HUC-1) and bladder cancer cells (MGH)
were investigated. The two types of cells were exposed to urine
for different lengths of time up to 6 h and MR spectroscopy was
carried out following fixation of the SV-HUC-1 and MGH cells.
First, 40 urine-stressed SV-HUC-1 cell spectra were com-
pared with 40 urine-stressed MGH cell spectra to assess the
ability of multivariate analyses of MR spectra to differentiate be-
tween SV-HUC-1 and MGH cells after exposing them to urine
for 6 h. The plots of the first two PCs against each other for
MR spectra of stressed SV-HUC-1 and MGH cells are shown
in Fig. 5.
PCA comparing the MR spectra of HUC cells exposed to
urine for 6 h show distinct, separate clusters for the two stressed
cell types. Even after 6 h exposure sensitivity and specificity are
quite high: 80% sensitivity and 87% specificity compared to the
control (0 h in urine) samples (sensitivity: 98% and specificity:
95%). The reason for the decrease could be the detrimental
effect of urine on the biochemistry of the cells causing a reduc-
tion of the signal-to-noise ratio in the MR spectra. Exposure to
urine did affect the spectra, however multivariate analyses of the
MR spectra could still discriminate between urothelial cells and
bladder cancer cells which support the robustness of modulated
Raman spectroscopy.
To gain a deeper understanding of the effect of urine on
the biochemical signatures of SV-HUC-1 and MGH cells, 40
Fig. 6 PCA of individual MR spectra of (a) urine-stressed urothelial
cells (SV-HUC-1) and (b) urine-stressed bladder cancer cells (MGH).
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Table 1 Confusion matrix giving the classification for urine-stressed
SV-HUC-1 and urine-stressed MGH.
SV-HUC-1 MGH
Predicted classification
True classification 30 min 3 h 6 h 30 min 3 h 6 h
30 min 39 1 0 29 2 9
3 h 2 36 2 2 34 4
6 h 4 3 33 4 3 33
urine-stressed SV-HUC-1 cell spectra from each time point were
compared with each other to determine whether multivariate
analyses can correctly predict how long the cells are exposed
to urine [Fig. 6(a)]. The same analysis was carried out on 40
urine-stressed MGH cell spectra [Fig. 6(b)].
PCA comparing the MR spectra of normal SV-HUC-1 cells
exposed to urine for 30 min, 3 and 6 h [Fig. 6(a)] shows distinct,
separate clusters for each group of stressed cells. In particu-
lar, the cells exposed to urine for 6 h are distinctly separated
from the other clusters, probably due to larger alterations of
their biochemical signatures caused by the long exposure to
urine. A similar trend can be observed for urine-stressed MGH
cells [Fig. 6(b)] with well-separated clusters for each group of
stressed cells. The separation of clusters of SV-HUC-1 cells is
more pronounced than those from MGH cells, which may reflect
differences in the rate of DNA breakdown and protein damage
in the urine-stressed cells.
The main result of this analysis is the creation of a confusion
matrix corresponding to the leave-one-out predictive classifica-
tion of SV-HUC-1 after 30 min, 3 and 6 h exposure to urine
(Table 1). The same confusion matrix was created for urine-
stressed MGH cells (Table 1). By analyzing the diagonal values
of the confusion matrixes for SV-HUC-1 and MGH, we can ob-
tain an overall predictive efficiency of about 90% for the urine-
stressed SV-HUC-1 and of about 75% for the stressed MGH.
These results suggest that MGH bladder cancer cells are more
sensitive to urine exposure than SV-HUC-1 urothelial cells. This
is consistent with the rapid decrease in the cell viability and re-
productive capacity of urine-stressed MGH cells compared to
SV-HUC-1 cells.
4 Conclusions
MRS was applied to the discrimination of urothelial cells and
bladder cancer cells from human cell lines exposed to urine.
The SR spectra of the control SV-HUC-1 and MGH cells
were classified with an efficiency of 85%, while the corre-
sponding MR spectra were identified with an efficiency of 97%,
demonstrating the superiority of MRS over SRS for the charac-
terization and classification of these cell types. We observed that
MR spectra of urine-stressed urothelial cells and bladder can-
cer cells succeeded in correctly predicting how long the cells
were exposed to urine with an efficiency of 95% for normal
SV-HUC-1 cells and 97% for cancer MGH cells.
The high sensitivity, specificity, and efficiency obtained from
multivariate analyses on MR spectra of urothelial cells and blad-
der cancer cells in urine demonstrates the great potential of MRS
as a rapid, inexpensive, and accurate clinical tool to detect the
presence of bladder cancer cells in urine samples.
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